bioRxivMicrobiology
Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro
H.-L. Xiong, J.-L. Cao, C.-G. Shen, J. Ma, X. Qiao, T. Shi, Y. Yang, S.-X. Ge, J. Zhang, T.-Y. Zhang, Q. Yuan, N.-S. Xia
Abstract
To identify drugs that are potentially used for the treatment of COVID-19, the potency of 1403 FDA-approved drugs were evaluated using a robust pseudovirus assay and the candidates were further confirmed by authentic SARS-CoV-2 assay. Four compounds, Clomiphene (citrate), Vortioxetine, Vortioxetine (hydrobromide) and Asenapine (hydrochloride), showed potent inhibitory effects in both pseudovirus and authentic virus assay. The combination of Clomiphene (citrate), Vortioxetine and Asenapine (hydrochloride) is much more potent than used alone, with IC50 of 0.34 M.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect after a Drug Repurposing Screen
J. Rodon, J. Munoz-Basagoiti, … N. Izquierdo-Useros·bioRxiv·Apr 23, 2020
- Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro
K. Shionoya, M. Yamasaki, … K. Watashi·bioRxiv·Nov 19, 2020
- Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection
- Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
- Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo
S. Weston, C. M. Coleman, … M. Frieman·bioRxiv·Mar 25, 2020
- Favipiravir, umifenovir and camostat mesylate: a comparative study against SARS-CoV-2
M. A. Unal, O. Besbinar, … A. Yilmazer·bioRxiv·Jan 11, 2022